Inhibition of HCV 3a core gene through Silymarin and its fractions
© Ashfaq et al; licensee BioMed Central Ltd. 2011
Received: 9 February 2011
Accepted: 1 April 2011
Published: 1 April 2011
Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan. Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high cost.
In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV 3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin (SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells
Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and combination of SM and its fractions with interferon will be a better option to treat HCV infection
HCV is a leading cause of variety of liver diseases varying from asymptomatic condition to hepatocellular carcinoma. HCV affects 270 million people worldwide and 10-15 million people are the carriers of HCV in Pakistan . It was estimated by the World Health Organization in 2004 that the annual deaths due to liver cancer caused by HCV and cirrhosis were 308,000 and 785,000, respectively . HCV is a blood-borne pathogen, which transmitted through parenteral exposure to contaminated blood or body fluids . Factors most strongly associated with HCV infection are blood transfusion (56%), alcohol consumption (44%) and intravenous drug abuse (31%) [3, 4]. Some other risk factors include use of inadequately sterilized medical equipment, high-risk sexual behaviors, and social or cultural practices such as body piercing, circumcision, and tattooing [5, 6].
Pegylated interferon (PEG-IFN) plus Ribavirin therapy is the current treatment for the patient with chronic hepatitis C. The main goal of therapy is to achieve a sustained virological response currently defined as undetectable HCV-RNA in peripheral blood determined with the most sensitive polymerase chain reaction technique 24 weeks after the end of treatment. This goal is practically equivalent with eradication of HCV infection and cure of the underlying HCV induced liver disease. This therapy cure only half number of patients due to side effects, resistance and high cost [7–10]. Hence, there is a need to develop anti-HCV agents, both from herbal sources and synthetic chemistry which are less toxic, more efficacious and cost-effective. The present study was undertaken to study the effect of SM and its fraction against HCV 3a core gene in liver cells. We report here that SM and its fractions effectively inhibited Core gene RNA and protein expression in a dose-dependant manner in Huh-7 cells.
Materials and methods
Extraction of Silybum marianum
The seeds of Silybum marianum were collected from Township market and SM was extracted as described by Polyak . Briefly, fine powder of seeds was made in a blender. Defatted the seed powder of Silybum marianum in n-hexane 2-3 times and extracted with aqueous acetone. The extract was concentrated to remove acetone, and then washed by hexane again to remove hydrophobic impurities. The remaining concentrate was treated with 1% NaCl solution to remove water soluble impurities. The precipitate and solid obtained through drying were combined together to form crude Silymarin. The crude SM was washed with aqueous ethanol and then dried completely to give the refined yellowish powder of SM.
Stock solution preparation
50 mg of SM was suspended in one ml of Dimethyl sulfoxide (DMSO) ensuring stock concentration of 50 μg/μl. Sieving the above solution by using 0.22 um filter inside Laminar Flow Hood, storing at -20°C.
The Huh-7 cell line was offered by Dr. Zafar Nawaz (Biochemistry and Molecular Biology Department, University of Miami, USA). Huh-7 cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum & 100 IU/ml penicillin & 100 μg/ml streptomycin, at 37°C in an atmosphere of 5% CO2.
For the construction of expression plasmid, viral RNA was extracted from 100 μl serum aliquots using Gentra RNA isolation kit (Gentra System Pennsylvania, USA) according to the manufacturer's instructions. About 200 ng RNA was used for RT-PCR using the SuperScript III one-step RT-PCR system (Invitrogen Life technologies, USA). HCV complementary DNA (cDNA) encoding the full length Core protein (amino acid 1-191 of HCV-3a) were amplified and cloned into pCR3.1 mammalian expression plasmid (kindly provided by Dr. Zafar Nawaz, University of Miami, USA) with FlagTAG inserted at the 5' end of the Core gene with EcoRV and XbaI restriction sites.
MTT assay for toxicity
To investigate cellular toxicity, 2×104 cells/well was plated into 96-well plates. After 24 h, different concentrations of SM were added and the plate was sealed and kept at 37°C in an atmosphere of 5% CO2 for 24 h. After the herbal extracts treatment was over, removed the media and SM. 100 μl fresh media and 20 μl of MTT solution (5 mg/ml in PBS) were added to all wells in Columns 1-11. Wrapped the plate in aluminum foil and incubated for 3-4 h at 37°C. Media was carefully removed and added 100 μl of DMSO to dissolve the formazan crystals in Columns 1-11. MTT formazan product was determined by measuring absorbance with an enzyme-linked immunosorbent assay (ELISA) plate reader at a test wavelength of 570 nm and a reference wavelength of 620 nm.
Antiviral activity of SM and its fractions against HCV 3a core gene
For transfection studies, Huh-7 cells (5×104) were plated in 24-well plates for 24 h. The medium was removed and cells were washed with 1X PBS. Cells were transiently transfected with expression plasmids containing HCV 3a core gene (0.4 μg) in the presence and absence of SM, its fractions and interferon by using Lipofectamine™ 2000 (Invitrogen life technologies, Carlsbad, CA) according to the manufacturer's protocol. Total RNA was extracted by using Trizol reagent (Invitrogen life technologies, Carlsbad, CA) according to the manufacturer's protocol. To analyze the effect of SM against HCV 3a core gene, cDNA was synthesized with 1 μg of RNA, using Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot/Germany). Gene expression analysis was carried out via PCR (Applied Biosystems Inc, USA) by using 2X PCR Mix (Fermentas). Following primers were used for the amplification of HCV Core forward primer: GGACGACGATGACAAGGACT; HCV core reverse: GGCTGTGACCGTTCAGAAGT; GAPDH Forward: ACCACAGTCCATGCCATCAC: and GAPDH reverse; TCCACCACCCTGTTGCTGTA PCR was performed by initial denaturation at 95°C for 5 min followed by 30 cycles, each of denaturation at 92°C for 45 s, annealing at 58°C for 45 s, and extension at 72°C for 1 min, with final extension at 72°C for 10 min. The amplified DNA samples were analyzed on 2% agarose gel. The DNA bands were visualized directly under the UV and the photographs of the gels were obtained with gel documentation system.
To determine the protein expression levels of HCV 3a core, the transfected and non-transfected cells were lysed with ProteoJET mammalian cell lysis reagent (Fermentas, Canada). Equal amounts of total protein were subjected to electrophoresis on 12% SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane following the manufacturer's protocol (Bio-Rad, CA). After blocking non-specific binding sites with 5% skimmed milk, blots were incubated with primary monoclonal antibodies specific to HCV Core and GAPDH (Santa Cruz Biotechnology Inc, USA) and secondary Horseradish peroxidase-conjugated anti-goat anti-mouse antibody (Sigma Aldrich, USA). The protein expressions were evaluated using chemiluminescence's detection kit (Sigma Aldrich, USA).
Purification of SM fractions
Purification of SM fractions was done through thin layer chromatography. Briefly, 1% sample solution was prepared in 5 ml solvent and was filtered. Took a TLC card and cut it in 10 cm length and 5 cm width. Small spot of sample was marked on plate. Dried and placed it in chromatography tank having ethyl acetate: chloroform (60: 40) as mobile phase and allowed it to run for one and a half hour. Then, solvent front was marked and chromatogram was dried. TLC chromatogram was observed under UV lamp at wavelength of 254 nm and 366 nm. Separation of components was good and spots of different colors were observed. Pattern of spots was recorded and R f value of each spot was determined.
Toxicological analysis of SM
Antiviral effect of SM against HCV 3a Core gene
Purification of different fractions of SM by thin layer chromatography
HCV infection is a serious global health problem that affects 180 million people worldwide and 10 million people in Pakistan. Currently, no vaccine is available for prevention of HCV infection due to high degree of strain variation. The current treatment with PEG-INFα in combination with ribavirin is costly, has significant side effects and fail to cure about one half of all infections [13, 14]. Hence, there is a need to develop other anti-HCV agents, which are less toxic, more efficacious and cost-effective. It is well known that medicinal plants have been used for centuries against different diseases including viral diseases and were therefore, used during the last century to identify, isolate and purify new compounds to treat viral and bacterial diseases. Many traditional medicinal plants and herbs were reported to have strong antiviral activity against DNA and RNA viruses by inhibiting virus replication, interfering with virus-to-cell binding and immunomodulation actions [15, 16]. HCV structural proteins (core, E1 and E2) and nonstructural proteins (NS3 protease and NS5B RNA-dependent RNA polymerase) are potent molecular targets of new antiviral compounds.
Silybum marianum is a flavolignin commonly known as 'milk thistle'. Silybum marianum has been shown to have clinical applications in the treatment of toxic hepatitis, fatty liver, cirrhosis, ischemic injury, radiation toxicity, and viral hepatitis. SM has been found to suppress nuclear factor kappa B (NF kB) dependent gene expression and also has inhibitory action on inflammatory and cytotoxic cascade of events induced by the viral infection (Saller et al., 2001). SM has anti-oxidative effect by inhibiting free radicals such as superoxide radical, hydroxyl radical (OH), hydrogen peroxide (H2O2), and lipid peroxide radicals . SM has been shown to inhibit the growth of endothelial , lung tumor , prostate cancer , and human hepatoma HepG2 and Hep3B cells. The anti-proliferative actions of SM are due to inhibition of signaling pathways that regulate the cell cycle including Akt and cyclin-dependent kinases. SM is a complex mixture of four flavonolignan isomers, namely silybin, isosilybin, silydianin and silychristin with an empirical formula C25H22O10. Silybin is the major and most active component and represents about 60-70 percent, followed by silychristin (20%), silydianin (10%), and isosilybin (5%) . SM plays an important part in modulating cell membrane and membrane receptors by inhibiting the binding of epidermal growth factor . Thus, SM shows hepatoprotective effect by alterations in the hepatic membrane. However, the results, of different clinical trials show that SM reduces liver enzymes such as ALT and AST associated with hepatitis . Treatment of 50 HCV patients with a mix of 7 antioxidants including SM also reduced ALT levels in 44% of patients, and reduced viral load in 25% of patients . SM has anti-proliferative properties due to the modulation of specific signaling pathways, transcription factors and gene expression . SM also effect on hepatic stellate cells (HSC) and decreases HCV-induced fibrosis . A recently published clinical trial, shows that high doses of intravenous silibinin results potent antiviral activity against HCV infected patient .
HCV Core protein modulates gene transcription, cell proliferation, cell death and cell signaling, interferes with metabolic genes and suppresses host immune response  leading to oxidative stress, liver steatosis and eventually hepatocellular carcinoma . Core protein is also able to up-regulate cyclooxygenase-2 (Cox-2) expression in hepatocytes derived cells, providing a potential mechanism for oxidative stress . The expression of Cox-2 in HCC was found to correlate with the levels of several key molecules implicated in carcinogenesis such as inducible nitric oxide synthetase (iNOS), activate vascular endothelial growth factor (VEGF) and phosphorylated Akt (p-Akt) [31, 32]. In this study, SM was examined for toxicological analysis in Huh-7 line. Our data show that SM is non toxic at a concentration up to 20 μg but when exceed from 30 μg SM show toxic effect in both liver and fibroblast cells (Figure 1). The study of Polyak et al also agreed with the statement that SM has non toxic up to 20 μg concentration . After toxicological analysis, antiviral effect against HCV core gene of 3a genotype was analyzed and our results showed that SM resulted in dose-dependent inhibition of HCV core gene similar to interferon alpha 2a (Figure 2). This may be due to stimulation of interferon pathway by phosphorylation of Stat1 on tyrosine and serine . SM may have effective on hepatocyte membranes, interferon receptor, inhibit of negative regulators of the Jak-Stat pathway such as SH2-containing phosphatases, the protein inhibitors of activated STATs, or the suppressors of cytokine signaling proteins such as SOCS 1 and SOCS 3 proteins . Studies in cell culture models have suggested a role for SOCS3 in HCV IFN resistance. HCV core protein over-expression has been reported to induce SOCS3 in cell culture models, resulting in impaired IFN signaling. HCV replicon cells resistant to IFN therapy have been shown to produce higher levels of SOCS3; inhibition of SOCS3 expression results in production of interferon . Furthermore, several in-vivo studies have shown that hepatic SOCS3 expression is associated with response to IFN treatment. Other possible mechanism could involve such as IRF3 or IRF9 and MAPK pathways . In order to identify the active ingredient against HCV, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Two fractions (S1 and S2) out of four showed antiviral effect against HCV core gene expression or function. These results showed that SM contains potential phytochemicals such as S1 and S2 and combination of these agents with interferon is helpful to cure HCV infection.
Usman Ali Ashfaq (PhD Molecular Biology), Tariq Javed (M.Phil pharmaceutical chemistry, Sidra Rehman (MSc Chemistry) and Sheikh Riazuddin (PhD molecular Biology and Dean Post graduate study at Allama Iqbal medical college, Lahore.
- HCV :
Hepatitis C virus
- SM :
- Huh-7 :
Human Hepatoma Cell line.
Financial support by Higher Education Commission Pakistan is highly acknowledged.
- Raja NSJK: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. J Microbiol Immunol Infect 2008, 41: 4-8.PubMedGoogle Scholar
- WHO: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6: 35-47. 10.1046/j.1365-2893.1999.6120139.xView ArticleGoogle Scholar
- Scannell KM, Willard CC, Seeff LB: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 2002, 36: S3-S20.Google Scholar
- Barazani Y, Hiatt JR, Tong MJ, Busuttil RW: Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007, 31: 1243-1248. 10.1007/s00268-007-9041-3View ArticlePubMedGoogle Scholar
- Saleem NH, Adrien A, Razaque A: Risky sexual behavior, knowledge of sexually transmitted infections and treatment utilization among a vulnerable population in Rawalpindi, Pakistan. Southeast Asian J Trop Med Public Health 2008, 39: 642-648.PubMedGoogle Scholar
- Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G: A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006, 13: 775-782. 10.1111/j.1365-2893.2006.00742.xView ArticlePubMedGoogle Scholar
- Flamm SL: Chronic hepatitis C virus infection. Jama 2003, 289: 2413-2417. 10.1001/jama.289.18.2413View ArticlePubMedGoogle Scholar
- Cornberg M, Wedemeyer H, Manns MP: Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002, 4: 23-30. 10.1007/s11894-002-0034-yView ArticlePubMedGoogle Scholar
- Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998, 46: 563-570. 10.1046/j.1365-2125.1998.00836.xPubMed CentralView ArticlePubMedGoogle Scholar
- Russo MW, Fried MW: Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124: 1711-1719. 10.1016/S0016-5085(03)00394-9View ArticlePubMedGoogle Scholar
- Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY: Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007, 132: 1925-1936. 10.1053/j.gastro.2007.02.038View ArticlePubMedGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4View ArticlePubMedGoogle Scholar
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339: 1485-1492. 10.1056/NEJM199811193392101View ArticlePubMedGoogle Scholar
- Moore MM, Elpern DJ, Carter DJ: Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004, 140: 215-217. 10.1001/archderm.140.2.215PubMedGoogle Scholar
- Amoros M, Fauconnier B, Girre RL: In vitro antiviral activity of a saponin from Anagallis arvensis, Primulaceae, against herpes simplex virus and poliovirus. Antiviral Res 1987, 8: 13-25. 10.1016/0166-3542(87)90084-2View ArticlePubMedGoogle Scholar
- Yao XJ, Wainberg MA, Parniak MA: Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 1992, 187: 56-62. 10.1016/0042-6822(92)90294-YView ArticlePubMedGoogle Scholar
- Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO: Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994, 91: 51-63. 10.1016/0009-2797(94)90006-XView ArticlePubMedGoogle Scholar
- Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R: Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005, 24: 1188-1202. 10.1038/sj.onc.1208276View ArticlePubMedGoogle Scholar
- Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R: Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004, 10: 8641-8647. 10.1158/1078-0432.CCR-04-1435View ArticlePubMedGoogle Scholar
- Singh RP, Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006, 45: 436-442. 10.1002/mc.20223View ArticlePubMedGoogle Scholar
- Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 2001, 61: 2035-2063. 10.2165/00003495-200161140-00003View ArticlePubMedGoogle Scholar
- Sharma Y, Agarwal C, Singh AK, Agarwal R: Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 2001, 30: 224-236. 10.1002/mc.1032View ArticlePubMedGoogle Scholar
- Liu J, Manheimer E, Tsutani K, Gluud C: Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003, 98: 538-544. 10.1111/j.1572-0241.2003.07298.xView ArticlePubMedGoogle Scholar
- Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, et al.: Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005, 39: 737-742. 10.1097/01.mcg.0000174023.73472.29View ArticlePubMedGoogle Scholar
- Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R: p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007, 6: 2696-2707. 10.1158/1535-7163.MCT-07-0104View ArticlePubMedGoogle Scholar
- Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009, 50: 1102-1111. 10.1016/j.jhep.2009.02.023View ArticlePubMedGoogle Scholar
- Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135: 1561-1567. 10.1053/j.gastro.2008.07.072View ArticlePubMedGoogle Scholar
- Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. Hepatology 2004, 39: 5-19. 10.1002/hep.20032View ArticlePubMedGoogle Scholar
- Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4: 1065-1067. 10.1038/2053View ArticlePubMedGoogle Scholar
- Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136/gut.2003.038364PubMed CentralView ArticlePubMedGoogle Scholar
- Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 29: 688-696. 10.1002/hep.510290355View ArticlePubMedGoogle Scholar
- Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001, 7: 1325-1332.PubMedGoogle Scholar
- Wormald S, Hilton DJ: Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279: 821-824. 10.1074/jbc.R300030200View ArticlePubMedGoogle Scholar
- Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La Mura V, Moschella F, Masutti F, et al.: Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007, 46: 1009-1015. 10.1002/hep.21782View ArticlePubMedGoogle Scholar
- Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 2003, 101: 4667-4679. 10.1182/blood-2002-12-3647View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.